Energy Transfer between AGuIX Nanoparticles and Photofrin under Light or X-ray Excitation for PDT Applications.

Fiche publication

Date publication

août 2024

Journal

Pharmaceuticals (Basel, Switzerland)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FROCHOT Céline , Dr DAOUK Joël

Tous les auteurs :
Dhaini B, Arnoux P, Daouk J, Lux F, Tillement O, Hagège A, Hamieh T, Shafirstein G, Frochot C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39204138

Résumé

Photodynamic therapy is an accepted therapy cancer treatment. Its advantages encourage researchers to delve deeper. The use of nanoparticles in PDT has several advantages including the passive targeting of cancer cells. The aim of this article is to evaluate the effectiveness of AGuIX nanoparticles (activation and guiding of irradiation by X-ray) in the presence or absence of a photosensitizer, Photofrin, under illumination of 630 nm or under X-ray irradiation. The goal is to improve local tumor control by combining PDT with low-dose-X-ray-activated NPs in the treatment of locally advanced metastatic lung cancer. The study of the energy transfer, which occurs after excitation of Gd/Tb chelated in AGuIX in the presence of Photofrin, was carried out. We could observe the formation of singlet oxygen after the light or X-ray excitation of Gd and Tb that was not observed for AGuIX or Photofrin alone, proving that it is possible to realize energy transfer between both compounds.